文献速递复苏、休克与脓毒症呼吸衰竭与机械通气重症综合管理与镇静镇痛

氢化可的松与抗坏血酸协同预防和修复脂多糖诱导的肺内皮屏障功能障碍

Hydrocortisone and Ascorbic Acid Synergistically Prevent and Repair Lipopolysaccharide-Induced Pulmonary Endothelial Barrier Dysfunction.
PubMed 文献 · Chest · 2017-07-21
一句话结论体外实验显示氢化可的松与抗坏血酸联用(而非单用)可显著逆转脂多糖诱导的肺微血管内皮屏障功能障碍,可能与p53、cofilin、RhoA及肌球蛋白轻链磷酸化通路有关。

该研究在人肺微血管内皮细胞上观察脂多糖(LPS)诱导的屏障功能障碍,并比较单用氢化可的松(HC)、单用抗坏血酸(vitC)及两者联用的效果。LPS单独导致跨内皮电阻显著下降(高通透性);vitC单用无屏障增强作用,也不影响LPS所致高通透性;HC单用仅有轻微屏障增强和保护作用;而HC与vitC联用(预处理或后处理)均显著逆转LPS诱导的屏障功能障碍。该屏障保护效应伴随LPS诱导的p53和磷酸化cofilin下调、RhoA激活及肌球蛋白轻链磷酸化的逆转。作者认为这为HC与vitC在脓毒症患者中的治疗效应提供了可能的机制通路。

要点

  • 体外实验中,LPS单独作用导致人肺微血管内皮细胞跨内皮电阻下降,表现为显著高通透性。
  • vitC单用既不增强内皮屏障,也不影响LPS诱导的高通透性;HC单用仅有轻微屏障增强和保护作用。
  • HC与vitC联用(无论预处理还是后处理)均显著逆转LPS诱导的内皮屏障功能障碍。
  • 屏障保护效应与LPS诱导的p53、磷酸化cofilin下调及RhoA激活、肌球蛋白轻链磷酸化被逆转相关。
  • 作者认为该结果提示一条可能解释HC与vitC在脓毒症患者中治疗效应的通路。

适用人群与场景

  • 人肺微血管内皮细胞体外实验,用于模拟脓毒症相关肺毛细血管通透性升高。

研究设计与关键结果

  • 研究类型为体外细胞实验,人肺微血管内皮细胞暴露于脂多糖(LPS),分别在不加或加入氢化可的松(HC)与抗坏血酸(vitC)的条件下观察。
  • LPS单独诱导显著高通透性,表现为跨内皮电阻值下降。
  • vitC单用未表现出屏障增强特性,也未影响LPS诱导的高通透性;HC单用仅表现出轻微的屏障增强和保护效应。
  • HC与vitC联用(预处理或后处理)均显著逆转LPS诱导的屏障功能障碍。
  • HC与vitC的屏障保护效应与LPS诱导的p53和磷酸化cofilin下调、RhoA激活及肌球蛋白轻链磷酸化的逆转相关。

证据类型、等级与局限

  • 证据类型:体外细胞实验(实验研究)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为该数据提供了一种新的内皮屏障保护机制,并提示一条可能解释HC与vitC在脓毒症患者中治疗效应的通路。
  • 原文为体外实验,未给出临床用药剂量、给药途径或疗程。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Sepsis refers to the dysregulated host immune response elicited by microbial infections resulting in life-threatening organ dysfunction. Sepsis represents a medical challenge, since it is associated with a rate of death as high as 60%. Septic shock is strongly associated with vascular dysfunction and elevated pulmonary capillary permeability. We recently reported that the combination of hydrocortisone (HC), ascorbic acid (vitC), and thiamine dramatically improves outcomes and reduces mortality in patients with sepsis. In the present study, we provide experimental evidence in support of the hypothesis that the combination of HC and vitC enhances endothelial barrier function.

METHODS: Human lung microvascular endothelial cells were exposed to lipopolysaccharide (LPS) in the absence or presence of HC and vitC.

RESULTS: LPS alone induced profound hyperpermeability, as reflected in decreased values of transendothelial electrical resistance. vitC alone did not exhibit barrier enhancement properties nor did it affect the LPS-induced hyperpermeability. Similarly, HC alone exhibited only a minor barrier-enhancing and protective effect. Conversely, the combination of HC and vitC, either as before or after treatment, dramatically reversed the LPS-induced barrier dysfunction. The barrier-protective effects of HC and vitC were associated with reversal of LPS-induced p53 and phosphorylated cofilin downregulation and LPS-induced RhoA activation and myosin light chain phosphorylation.

CONCLUSIONS: These data provide a novel mechanism of endothelial barrier protection and suggest one possible pathway that may contribute to the therapeutic effects of HC and vitC in patients with sepsis.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Barabutis N, Khangoora V, Marik PE, et al. Hydrocortisone and Ascorbic Acid Synergistically Prevent and Repair Lipopolysaccharide-Induced Pulmonary Endothelial Barrier Dysfunction. Chest. 2017. PMID: 28739448. doi:10.1016/j.chest.2017.07.014

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。